Thank you to our speakers, sponsors, and delegates who joined us in Boston, MA for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Successfully Navigated Regulations, Unveiled Clear Routes to Commercialization & Optimized Test Selection to Accelerate Patient Access to Personalized Medicines for Improved Disease Outcomes in Oncology & Beyond

The 14th World Clinical Biomarkers & Companion Diagnostics Summit returned this September 2024 as the leading forum for diagnostic stakeholders. This 2024, attendees enjoyed an extended four-day agenda packed with new content and enhanced networking opportunities, uniting drug developers, diagnostics providers, payers and coalitions to share insights and accelerate biomarker-driven clinical trials.

Whether attendees were working with small molecules, large biologics, or other modalities, this year’s agenda was carefully curated to strengthen their early disease biomarker discovery, clinical biomarker strategy, reimbursement clarity, and drug-diagnostics commercialization. Attendees joined over 500 fellow senior leaders across Biomarkers, Translational Medicine, Precision Medicine, Companion Diagnostics, Commercialization, Regulation, and more to drive the future of precision medicine and improve patient outcomes.

2024 EVENT GUIDE

Screenshot 2024-06-05 150616

2024 Expert Speakers:

Amanda Wang

Vice President - Translational Science Leader

Bayer

Ann Fish-Steagall

Senior Vice Preisdent - Patient Services & Healthcare Delivery

LUNGevity Foundation

Doris Kim

Vice President - Translational Sciences

Zentalis Pharmaceuticals

Gerard Sanderink

Global Head - Biomarkers & Clinical Bioanalyses

Sanofi

Jennifer Dacpano-Komansky

Executive Director - Regulatory Affairs Precision Medicine Lead

Novartis

Mark Gustavson

Senior Director & Global Head Computational Pathology Translational Science

AstraZeneca

Michael Montalto

Vice President - Precision Medicine

Amgen

Tricia Bal

Head - Oncology Precision Medicine, Global Commercial Strategy

Johnson & Johnson Services, Inc

What Was New for 2024:

1

A Whole New Day

Attendees got involved in 3 full days of data-driven content and interactive discussions this year, with an additional 3.5 hours dedicated to networking, providing actionable insights, industry connections, and cutting-edge knowledge to keep you ahead of the curve.

2

35 New Biopharma Speakers

Attendees heard from 35 new Key Opinion Leaders pioneering new data, advancing better technologies, and improving regulatory strategies in precision medicine from companies including AstraZeneca, Johnson & Johnson, Zentalis and more.

3

Brand New Content

Key topic areas included CDx in ADCs, LDT updates, generative AI and unsupervised learning models, transformative fluid biomarkers, non-invasive digital biomarkers and non-oncology biomarkers.

Companies that Attended in 2024:

40926 - companies

2024 Partners:

Other Events in the Series